Archive · 15 Sep 2026
India Could Have First Indigenous Dengue Vaccine By 2027
India is testing a dengue vaccine made in the country.
The vaccine is now in a large study called a phase 3 clinical trial.
This study checks whether the vaccine is safe and works well.
Some people receive the vaccine, while others are in a comparison group.
Researchers watch everyone for a period of time.
They must finish collecting information before checking the final results.
There have been relatively few dengue cases in India this year.
Because of that, researchers may need more time before revealing which participants received the vaccine.
India could receive its first indigenous dengue vaccine by 2027, according to the ICMR director general.
The vaccine is undergoing phase 3 clinical trials to assess its safety and effectiveness in a larger population.
Researchers are comparing participants who receive the vaccine with a control or placebo group.
The trial team must complete follow-up and analyse the data before formally assessing the results.
Fewer dengue cases in India this year may require researchers to wait longer before unblinding the trial results.
- Who
- The Indian Council of Medical Research and researchers conducting the vaccine trial; the ICMR director general provided the timeline.
- What
- A possible first indigenous Indian dengue vaccine is undergoing phase 3 clinical trials and could be available by 2027.
- When
- The projected timeline is 2027; the trial results may take longer to unblind because of this year’s low dengue case numbers.
- Where
- India.
- Why
- Researchers must complete participant follow-up and analyse the trial data to determine whether the vaccine is safe and effective.
- Projected timeline
- India could get its first indigenous dengue vaccine by 2027.
- Trial stage
- Phase 3 clinical trials.
- Trial purpose
- To assess the vaccine’s safety and effectiveness in a much larger population.
- Comparison group
- Researchers are comparing vaccinated participants with a control or placebo group.
- Required steps
- The planned follow-up must be completed and the data analysed before formal assessment.
- Potential delay
- Relatively few dengue cases in India this year could mean a longer wait before unblinding the results.